{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:52:32Z","timestamp":1793976752101,"version":"4.8.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s10157-023-02379-1","type":"journal-article","created":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T11:01:52Z","timestamp":1690282912000},"page":"901-911","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["N-methyl-2-pyridone-5-carboxamide (N-Me-2PY) has potent anti-fibrotic and anti-inflammatory activity in a fibrotic kidney model: is it an old uremic toxin?"],"prefix":"10.1007","volume":"27","author":[{"given":"Norito","family":"Yoshimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsutoshi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Notoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Yukioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Wakino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,25]]},"reference":[{"key":"2379_CR1","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","volume":"385","author":"GBD 2013 Mortality and Causes of Death Collaborators","year":"2015","unstructured":"GBD 2013 Mortality and Causes of Death Collaborators. 2015 Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385:117\u201371.","journal-title":"Lancet"},{"key":"2379_CR2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1053\/j.ajkd.2021.11.010","volume":"80","author":"M Ruiz-Ortega","year":"2022","unstructured":"Ruiz-Ortega M, Lamas S, Ortiz A. Antifibrotic agents for the management of CKD: a review. Am J Kidney Dis. 2022;80:251\u201363.","journal-title":"Am J Kidney Dis"},{"key":"2379_CR3","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1046\/j.1523-1755.63.s84.43.x","volume":"63","author":"R Vanholder","year":"2003","unstructured":"Vanholder R, Glorieux G, De Smet R, et al. New insights in uremic toxins. Kidney Int. 2003;63:S6\u201310.","journal-title":"Kidney Int"},{"key":"2379_CR4","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1681\/ASN.2013101062","volume":"25","author":"R Vanholder","year":"2014","unstructured":"Vanholder R, Schepers E, Pletinck A, et al. The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review. J Am Soc Nephrol. 2014;25:1897\u2013907.","journal-title":"J Am Soc Nephrol"},{"key":"2379_CR5","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1681\/ASN.V1081815","volume":"10","author":"R Vanholder","year":"1999","unstructured":"Vanholder R, De Smet R. Pathophysiologic effects of uremic retention solutes. J Am Soc Nephrol. 1999;10:1815\u201323.","journal-title":"J Am Soc Nephrol"},{"key":"2379_CR6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41581-019-0216-6","volume":"16","author":"KM Ralto","year":"2020","unstructured":"Ralto KM, Rhee EP, Parikh SM. NAD(+) homeostasis in renal health and disease. Nat Rev Nephrol. 2020;16:99\u2013111.","journal-title":"Nat Rev Nephrol"},{"key":"2379_CR7","doi-asserted-by":"publisher","first-page":"6398","DOI":"10.1038\/s41598-022-10476-6","volume":"12","author":"R Takahashi","year":"2022","unstructured":"Takahashi R, Kanda T, Komatsu M, et al. The significance of NAD + metabolites and nicotinamide N-methyltransferase in chronic kidney disease. Sci Rep. 2022;12:6398.","journal-title":"Sci Rep"},{"key":"2379_CR8","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1046\/j.1523-1755.63.s84.36.x","volume":"63","author":"B Rutkowski","year":"2003","unstructured":"Rutkowski B, Slominska E, Szolkiewicz M, et al. N-methyl-2-pyridone-5-carboxamide: a novel uremic toxin? Kidney Int Suppl. 2003;63:S19-21.","journal-title":"Kidney Int Suppl"},{"key":"2379_CR9","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3390\/toxins8110339","volume":"8","author":"A Lenglet","year":"2016","unstructured":"Lenglet A, Liabeuf S, Bodeau S, et al. N-methyl-2-pyridone-5-carboxamide (2PY)-major metabolite of nicotinamide: an update on an old uremic toxin. Toxins (Basel). 2016;8:339.","journal-title":"Toxins (Basel)"},{"key":"2379_CR10","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1681\/ASN.2008090931","volume":"20","author":"SP RamachandraRao","year":"2009","unstructured":"RamachandraRao SP, Zhu Y, Ravasi T, et al. Pirfenidone is renoprotective in diabetic kidney disease. J Am Soc Nephrol. 2009;20:1765\u201375.","journal-title":"J Am Soc Nephrol"},{"key":"2379_CR11","doi-asserted-by":"publisher","first-page":"174503","DOI":"10.1016\/j.ejphar.2021.174503","volume":"911","author":"X Bai","year":"2021","unstructured":"Bai X, Nie P, Lou Y, et al. Pirfenidone is a renal protective drug: mechanisms, signalling pathways, and preclinical evidence. Eur J Pharmacol. 2021;911:174503.","journal-title":"Eur J Pharmacol"},{"key":"2379_CR12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrneph.2016.48","volume":"12","author":"XM Meng","year":"2016","unstructured":"Meng XM, Nikolic-Paterson DJ, Lan HY. TGF-\u03b2: the master regulator of fibrosis. Nat Rev Nephrol. 2016;12:325\u201338.","journal-title":"Nat Rev Nephrol"},{"key":"2379_CR13","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/ki.1993.19","volume":"43","author":"FN Ziyadeh","year":"1993","unstructured":"Ziyadeh FN. Renal tubular basement membrane and collagen type IV in diabetes mellitus. Kidney Int. 1993;43:114\u201320.","journal-title":"Kidney Int"},{"key":"2379_CR14","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0006-2952(02)01213-3","volume":"64","author":"MA Al-Bayati","year":"2002","unstructured":"Al-Bayati MA, Xie Y, Mohr FC, et al. Effect of pirfenidone against vanadate-induced kidney fibrosis in rats. Biochem Pharmacol. 2002;64:517\u201325.","journal-title":"Biochem Pharmacol"},{"key":"2379_CR15","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1046\/j.1523-1755.1998.00962.x","volume":"54","author":"T Shimizu","year":"1998","unstructured":"Shimizu T, Kuroda T, Hata S, et al. Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney Int. 1998;54:99\u2013109.","journal-title":"Kidney Int"},{"key":"2379_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ejps.2014.02.014","volume":"58","author":"E Conte","year":"2014","unstructured":"Conte E, Gili E, Fagone E, et al. Effect of pirfenidone on proliferation, TGF-\u03b2-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur J Pharm Sci. 2014;58:13\u20139.","journal-title":"Eur J Pharm Sci"},{"key":"2379_CR17","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/ndt\/gfu196","volume":"30","author":"A Lan","year":"2015","unstructured":"Lan A, Du J. Potential role of Akt signaling in chronic kidney disease. Nephrol Dial Transplant. 2015;30:385\u201394.","journal-title":"Nephrol Dial Transplant"},{"key":"2379_CR18","doi-asserted-by":"publisher","first-page":"696542","DOI":"10.3389\/fcell.2021.696542","volume":"9","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Jin D, Kang X, et al. Signaling pathways involved in diabetic renal fibrosis. Front Cell Dev Biol. 2021;9:696542.","journal-title":"Front Cell Dev Biol"},{"key":"2379_CR19","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/ki.2008.160","volume":"74","author":"AB Rodr\u00edguez-Pe\u00f1a","year":"2008","unstructured":"Rodr\u00edguez-Pe\u00f1a AB, Grande MT, Eleno N, et al. Activation of Erk1\/2 and Akt following unilateral ureteral obstruction. Kidney Int. 2008;74:196\u2013209.","journal-title":"Kidney Int"},{"key":"2379_CR20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1124\/mol.62.1.65","volume":"62","author":"GJ Inman","year":"2002","unstructured":"Inman GJ, Nicol\u00e1s FJ, Callahan JF, et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol. 2002;62:65\u201374.","journal-title":"Mol Pharmacol"},{"key":"2379_CR21","doi-asserted-by":"publisher","first-page":"118454","DOI":"10.1016\/j.lfs.2020.118454","volume":"260","author":"MH Sharawy","year":"2020","unstructured":"Sharawy MH, Serrya MS. Pirfenidone attenuates gentamicin-induced acute kidney injury by inhibiting inflammasome-dependent NLRP3 pathway in rats. Life Sci. 2020;260:118454.","journal-title":"Life Sci"},{"key":"2379_CR22","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.molimm.2018.05.003","volume":"99","author":"Y Li","year":"2018","unstructured":"Li Y, Li H, Liu S, et al. Pirfenidone ameliorates lipopolysaccharide-induced pulmonary inflammation and fibrosis by blocking NLRP3 inflammasome activation. Mol Immunol. 2018;99:134\u201344.","journal-title":"Mol Immunol"},{"key":"2379_CR23","doi-asserted-by":"publisher","first-page":"F676","DOI":"10.1152\/ajprenal.00507.2012","volume":"304","author":"JF Chen","year":"2013","unstructured":"Chen JF, Ni HF, Pan MM, et al. Pirfenidone inhibits macrophage infiltration in 5\/6 nephrectomized rats. Am J Physiol Renal Physiol. 2013;304:F676-685.","journal-title":"Am J Physiol Renal Physiol"},{"key":"2379_CR24","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1093\/ndt\/gfx249","volume":"32","author":"A Lenglet","year":"2017","unstructured":"Lenglet A, Liabeuf S, El Esper N, et al. Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study. Nephrol Dial Transplant. 2017;32:870\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"2379_CR25","doi-asserted-by":"publisher","first-page":"E318","DOI":"10.1002\/ajh.24371","volume":"91","author":"C O'Connell","year":"2016","unstructured":"O\u2019Connell C, Horwood K, Nadamuni M. Correction of refractory thrombocytopenia and anemia following withdrawal of extended release niacin. Am J Hematol. 2016;91:E318.","journal-title":"Am J Hematol"},{"key":"2379_CR26","doi-asserted-by":"publisher","first-page":"F1283","DOI":"10.1152\/ajprenal.00441.2003","volume":"287","author":"K Ito","year":"2004","unstructured":"Ito K, Chen J, El Chaar M, et al. Renal damage progresses despite improvement of renal function after relief of unilateral ureteral obstruction in adult rats. Am J Physiol Renal Physiol. 2004;287:F1283-1293.","journal-title":"Am J Physiol Renal Physiol"},{"key":"2379_CR27","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1681\/ASN.2011121175","volume":"23","author":"F Duranton","year":"2012","unstructured":"Duranton F, Cohen G, De Smet R, et al. Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol. 2012;23:1258\u201370.","journal-title":"J Am Soc Nephrol"},{"key":"2379_CR28","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1681\/ASN.2010101049","volume":"22","author":"K Sharma","year":"2011","unstructured":"Sharma K, Ix JH, Mathew AV, et al. Pirfenidone for diabetic nephropathy. J Am Soc Nephrol. 2011;22:1144\u201351.","journal-title":"J Am Soc Nephrol"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-023-02379-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-023-02379-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-023-02379-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T08:05:29Z","timestamp":1697529929000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-023-02379-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,25]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["2379"],"URL":"https:\/\/doi.org\/10.1007\/s10157-023-02379-1","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,25]]},"assertion":[{"value":"25 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was funded and supported by SHIONOGI & Co. Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}